Analysts have clear opinions on BIO.

Bio-Rad Laboratories, Inc. (BIO) is followed by analysts on the street.

Patrick B Donnelly from Goldman Sachs rates it a Buy with a target of $400.00.

Similarly, 4 months ago Jack Meehan of Barclays Reiterated a Buy with a target of $380.00.

The consensus on the street is null.

What does Bio-Rad Laboratories, Inc.(BIO) do ?
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories, Inc. (BIO) Insider Trades

Multiple company employees have indulged in significant insider trading. Bio-Rad Laboratories, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

EVP, GC, Sec, Ernst Timothy S : S – Sale+OE(-$705,436) of BIO in the trading session of 2019-12-04.

VP, Corporate Controller Stark James R : S – Sale(-$298,030) of BIO in the trading session of 2019-11-11.

EVP Tumolo Annette : S – Sale(-$172,260) of Bio-Rad Laboratories, Inc. in the trading session of 2019-09-12.

Looking for stocks just like BIO?

Based on Wall Street analyst research, several stocks are similar to BIO
They are:
– HBIO [Info can be found here: ]
– DHR [Info can be found here: ]
– TMO [Info can be found here: ]